IMPALA-2 is a global, pivotal, Phase 3, 48-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the efficacy and safety of molgramostim 300 mcg self-administered once ...
Description: Kevin Davidson, M.D., FCCP, will provide an update on autoimmune pulmonary alveolar proteinosis, including the pathophysiology of this rare lung disease, signs and symptoms, diagnosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results